<div>Phase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)</div><div><br /></div><div>Target: PRAME</div>

Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)

Gebärmutterkrebs (Uteruskarzinom)

Gebärmutterhalskrebs (Zervixkarzinom)

Eierstockkrebs (Ovarialkarzinom)

Hauttumoren

Malignes Melanom

HLA (Humane Leukozytenantigene)

PRAME (Nuclear Receptor Transcriptional Regulator)

Phase I

IMA203-101 (Immatics-PRAME)

Drittlinie

> Drittlinie

A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab&#160;Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With&#160;Previously Untreated Advanced Melanoma (PRISM-MEL-301)

BRAF

RAF (rapidly accelerated fibrosarcoma)

BRAF V600

Phase III

Immunocore IMC-F106C-301

Erstlinie

Comprehensive Cancer Center Mainfranken

Studien des CCC Mainfranken